Drug Information

Drug General Information
Drug ID
D0D9LB
Former ID
DCL000316
Drug Name
BIBV 308
Drug Type
Small molecular drug
Indication Peripheral vascular disease [ICD9: 443.9; ICD10:I73.9] Phase 1 [524888]
Company
Boehringer Ingelheim
Structure
Download
2D MOL

3D MOL
Formula
C23H27N5O2
Canonical SMILES
CC(C)(C)N=C(NC#N)NC1=CC=CC(=C1)C(=CCCCC(=O)O)C2=CN=CC=C<br />2
InChI
1S/C23H27N5O2/c1-23(2,3)28-22(26-16-24)27-19-10-6-8-17(14-19)20(11-4-5-12-21(29)30)18-9-7-13-25-15-18/h6-11,13-15H,4-5,12H2,1-3H3,(H,29,30)(H2,26,27,28)/b20-11+
InChIKey
XUTLOCQNGLJNSA-RGVLZGJSSA-N
PubChem Compound ID
6449876
PubChem Substance ID
14855065, 15851354, 43041045, 47207735, 50750909, 57369989, 85210088, 103188568, 103968688, 114582828, 134338972, 135227576, 137126766, 137263972, 198978038, 226427449, 240359692
Target and Pathway
Target(s) Thromboxane A2 receptor Target Info Antagonist [536029]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Platelet activation
Reactome Prostanoid ligand receptors
G alpha (q) signalling events
G alpha (12/13) signalling events
Thromboxane signalling through TP receptor
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
Signal amplification
GPCR ligand binding
GPCR downstream signaling
References
Ref 524888ClinicalTrials.gov (NCT02223013) Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects. U.S. National Institutes of Health.
Ref 536029AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.